Company Overview
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.39.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -108.2%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -108.20% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -48.31% |
| 6 Months: | -56.13% |
| 3 Months: | +56.11% |
| 1 Month: | +71.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)58.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -108.2% CAGR over 5 years.
- Trading 64.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AARD Aardvark Therapeutics, Inc. R2K | 6.26 | -1.95 | $136.57M | 0.00% | -58.82% | -58.79% | - | -108.20% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 10.47M | 15.85M | 17.70M | 18.70M | 22.46M |
| Operating Income | -2.17M | -6.07M | - | - | -10.47M | -15.85M | -17.70M | -18.70M | -22.46M |
| EBITDA | - | - | - | - | -10.46M | -15.84M | -17.69M | -18.69M | -22.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -9.31M | -14.37M | -16.32M | -17.60M | -21.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -2.18M | -5.45M | - | - | -9.31M | -14.37M | -16.32M | -17.60M | -21.59M |
| Diluted EPS | -0.55 | -1.37 | - | - | -0.71 | -0.66 | -0.75 | -0.81 | -0.99 |
| R&D Expense | 1.21M | 4.03M | 4.07M | - | 7.75M | 13.14M | 13.74M | - | 16.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 10.87M | 6.65M | 22.67M | 62.73M |
| Operating Income | -10.87M | -6.65M | -22.67M | -62.73M |
| EBITDA | -10.76M | -6.65M | -22.65M | -62.69M |
| Interest Expense | - | - | - | - |
| Pretax Income | -13.56M | -7.21M | -20.59M | -57.59M |
| Tax Provision | - | - | - | - |
| Net Income | -13.56M | -7.21M | -20.59M | -57.59M |
| Diluted EPS | -1.39 | -0.56 | -0.96 | -2.93 |
| R&D Expense | - | - | 17.36M | 48.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 16.76M | 10.54M | 77.51M | 117.18M |
| Current Assets | 16.49M | 10.37M | 74.14M | 111.89M |
| Cash & Equivalents | 15.56M | 9.73M | 61.64M | 47.05M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 44.68M | 45.34M | 132.15M | 10.55M |
| Current Liabilities | 595.00K | 1.38M | 4.93M | 10.55M |
| Long Term Debt | - | - | - | - |
| Total Debt | 262.00K | 162.00K | 779.00K | 441.00K |
| Total Equity | -27.92M | -34.80M | -54.64M | 106.63M |
| Shares Outstanding | 21.38M | 21.38M | 21.69M | 21.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -10.54M | -5.82M | -18.09M | -54.17M |
| Investing Cash Flow | -1.00M | 0 | -12.00M | -49.67M |
| Financing Cash Flow | 225.00K | 0 | 81.99M | 89.25M |
| Capital Expenditure | - | - | -109.00K | -95.00K |
| Free Cash Flow | -10.54M | -5.82M | -18.20M | -54.27M |
| Net Change in Cash | -11.32M | -5.82M | 51.91M | -14.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 48.6% | 20.7% | 37.7% | -54.0% |
| ROCE % | -67.3% | -72.7% | -31.2% | -58.8% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AARD
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and
Top Midday Decliners
LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors
FDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeost…
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 07, 20…
AARD — Frequently Asked Questions
What is the current share price of Aardvark Therapeutics, Inc. (AARD)?
As of 2026-07-14 21:23 PDT, Aardvark Therapeutics, Inc. (AARD) trades at $6.26 on NasdaqGS. Its 52-week range is $3.48 to $17.41.
What is the market capitalisation of AARD?
Aardvark Therapeutics, Inc. (AARD) has a market capitalisation of $136.57M on NasdaqGS.
What is the P/E ratio of AARD?
AARD trades at a trailing price-to-earnings (P/E) ratio of -1.95. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.98.
What is the return on equity (ROE) of AARD?
AARD has a return on equity (ROE) of -58.79%. Its return on capital employed (ROCE) is -58.82%.
Is AARD a good stock to buy?
This page provides a data-driven analysis of Aardvark Therapeutics, Inc. (AARD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.